Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Airbnb, Inc. (ABNB) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance

Airbnb, Inc.Trade
Amylx Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Airbnb, Inc. vs Amylx Pharmaceuticals Inc — how do they compare? Airbnb, Inc. trades at $182.8 (market cap $110.76B), while Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B). The key difference: Airbnb, Inc. is far larger — about 42× Amylx Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

ABNBAMLX
Market Cap
$110.76B$2.64B
Sector
Consumer CyclicalHealth
52-Week High
$184.98$24.19
52-Week Low
$111.54$7.82
Enterprise Value
$101.19B$2.39B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Airbnb, Inc.

ABNB trades at $184.70, up 3.72% in 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving averages and recent earnings beat in Q2 2026. Revenue growth is steady, with 2025 revenue at $12.24 billion and net income of $2.51 billion, though Q4 2025 and Q1 2026 EPS missed expectations. Analyst sentiment is mixed with a consensus price target of $173.26, below the current price, and news highlights AI-driven growth initiatives.

Outlook is cautiously optimistic with AI expansion boosting bookings and margins, but high valuation ratios like a P/E of 42.23 pose risks. Competition and economic sensitivity are key concerns. Institutional holdings and bullish technical trends support upside potential if execution continues.

Amylx Pharmaceuticals Inc

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Airbnb, Inc.

Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.

Read more on ABNB

About Amylx Pharmaceuticals Inc

Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.

Read more on AMLX